Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review
Por:
Marks, DI, Cassaday, RD, Ribera, JM, Schuh, AC, Park, JH, Chiaretti, S and Stelljes, M
Publicada:
2 ene 2025
Ahead of Print:
1 ene 2025
Resumen:
IntroductionInotuzumab ozogamicin (InO) is indicated for the treatment of adults with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assessed outcomes by baseline characteristics for patients with R/R ALL treated with InO to identify which patients may benefit most.MethodsIn adherence with PRISMA guidelines, searches were run in Embase and MEDLINE. Inclusion criteria were real-world evidence, observational studies, and phase 2-4 trials. The Cochrane Risk of Bias tool and Newcastle-Ottawa instrument assessed quality.Results34 publications were included; 11 described the phase 3 INO-VATE trial. Patients treated with InO who were CD22-positive, in first salvage, and eligible for subsequent hematopoietic stem cell transplant (HSCT) had improved outcomes. Reduced incidence of veno-occlusive disease was observed in patients with normal transaminase levels and bilirubin, no prior liver disease, and who did not receive dual alkylators.ConclusionsThe ideal patient for InO treatment has CD22-positive disease (>= 20% leukemic blasts), normal liver function, no history of liver disease, is in first salvage, has not previously received HSCT, prefers outpatient treatment, or has high disease burden. Limitations included potentially missing publications that were non-English, not identified in the searches, or available after the date the searches were conducted.RegistrationThis systematic review was registered on the Prospective Register of Systematic Reviews (PROSPERO), registration number: CRD42022330496.
Filiaciones:
Marks, DI:
Univ Hosp Bristol NHS Trust, Dept Haematol, Horfield Rd, Bristol BS8 3AP, England
Cassaday, RD:
Univ Washington, Clin Res Div, Seattle, WA USA
Fred Hutchinson Canc Ctr, Seattle, WA USA
:
Inst Catala Oncol, Dept Hematol, Barcelona, Spain
Josep Carreras Res Inst, Barcelona, Spain
Schuh, AC:
Univ Toronto, Canc Clin Res Unit, Toronto, ON, Canada
Park, JH:
Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
Chiaretti, S:
Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
Stelljes, M:
Univ Munster, Dept Med A, Munster, Germany
Bronze
|